SKB BIO-B (06990) opened more than 5% higher, currently up 5.37% at HKD 483, with a trading volume of HKD 1.5939 million. The company announced that it presented several clinical research results at the 2025 European Society for Medical Oncology (ESMO) conference, being held in Berlin, Germany from October 17 to 21. The results include data on the anti-TROP2 antibody-drug conjugate sac-TMT (佳泰莱®), the anti-HER2 ADC A166 (舒泰莱®), and Claudin18.2 ADC SKB315.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.